【礼来(LLY.US)新药联用Wegovy减重效果佳!大摩唱多:股价有望上涨46%】智通财经APP获悉,当地时间6月23

智通财经
25 Jun
【礼来(LLY.US)新药联用Wegovy减重效果佳!大摩唱多:股价有望上涨46%】智通财经APP获悉,当地时间6月23日,礼来(LLY.US)在芝加哥举行的美国糖尿病协会(ADA)大会上公布的数据显示,其实验性药物Bimagrumab在与诺和诺德(NVO.US)的GLP-1类减肥药Wegovy(司美格鲁肽)联合使用后,能帮助患者在减重的同时维持肌肉量。研究发现,接受Bimagrumab与Wegovy联合治疗的患者在48周后体重降低22.1%,其中92.8%的体重减少来自身体脂肪。相比之下,仅使用Wegovy的试验患者体重降低15.7%,且71.8%的体重减少来自身体脂肪。这表明,与联用方案相比,单独使用Wegovy的患者会流失更多瘦肌肉量。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10